Catalog No. | HS870136 |
---|---|
Species reactivity | Human |
Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
Host species | Humanized |
Isotype | IgG4-kappa |
Expression system | Mammalian Cells |
Clonality | Monoclonal |
Target | Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279 |
Endotoxin level | Please contact the lab for this information. |
Purity | >95% purity as determined by SDS-PAGE. |
Purification | Protein A/G purified from cell culture supernatant. |
Accession | Q15116 |
Form | Liquid |
Storage buffer | 0.01M PBS, pH 7.4. |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names | HLX10, 2231029-82-4 |
Background | Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market. • The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870 • PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations., PMID:30888929 • The diverse functions of the PD1 inhibitory pathway., PMID:28990585 • PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy., PMID:30191996 • Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845 • PD-1 expression and clinical PD-1 blockade in B-cell lymphomas., PMID:29118007 • Overcoming T cell exhaustion in infection and cancer., PMID:25797516 • Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker., PMID:32875727 • Tumor Mutational Burden and Response Rate to PD-1 Inhibition., PMID:29262275 • PD-L1., PMID:29097600 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for Research Grade Serplulimab.
+33(0)3 90 20 54 70
19 rue de la Haye 67300 Schiltigheim France